Studying genetic tests for early hormone-positive breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how genetic tests like Oncotype DX or Mammaprint are used to guide treatment decisions for people with early-stage, hormone receptor-positive (HR+) and HER2-negative breast cancer. It aims to help doctors choose between hormone therapy alone or chemotherapy plus hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have early-stage breast cancer that is hormone receptor-positive (ER+ more than 10%) and HER2-negative
- You had surgery to remove your breast cancer, and your lymph nodes were checked
- Your cancer is considered intermediate risk (not low or high risk) based on specific clinical features
- Your doctor recommended a genomic test like Oncotype DX or Mammaprint to help guide your treatment
- You are able to give written consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether younger, premenopausal women with early-stage, hormone-sensitive breast cancer can safely use hormone therapy alone after surgery, based on their tumor's gene activity score (Oncotype DX). It aims to find the best treatment approach based on your cancer's biology.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This study looks at how well treatments work for people with early-stage, hormone receptor-positive, HER2-negative breast cancer when the Oncotype DX test helps guide therapy. It aims to understand real-world outcomes in French patients.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This study links breast tumor test results from MammaPrint and optional BluePrint (and full genetic data) with real-world clinical information to understand which new gene activity patterns matter. It may help future patients by improving how doctors use these tests to guide care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.